skip to content
The role of BCAR4 in tamoxifen resistant breast cancer Preview this item
ClosePreview this item
Checking...

The role of BCAR4 in tamoxifen resistant breast cancer

Author: Marcia Godinho
Publisher: Erasmus University Rotterdam 2012-06-27
Edition/Format: Book Book : English
Summary:
textabstractBreast cancer is one of the most common cancers in women, and it is the second leading cause of cancer-related deaths, just behind lung cancer. The antiestrogen tamoxifen has been successfully used for over three decades to treat patients with estrogen receptor alpha-positive breast cancer patients. However, resistance to this antiestrogen presents a major problem in the treatment of these patients. The  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Find a copy online

Links to this item

Find a copy in the library

We were unable to get information about libraries that hold this item.

Details

Document Type: Book
All Authors / Contributors: Marcia Godinho
ISBN: 978-94-6191-312-8
Language Note: English
Unique Identifier: 6892891139
Awards:

Abstract:

textabstractBreast cancer is one of the most common cancers in women, and it is the second leading cause of cancer-related deaths, just behind lung cancer. The antiestrogen tamoxifen has been successfully used for over three decades to treat patients with estrogen receptor alpha-positive breast cancer patients. However, resistance to this antiestrogen presents a major problem in the treatment of these patients. The breast cancer antiestrogen resistance 4 (BCAR4) gene was identified earlier as a gene capable of inducing tamoxifen resistance in breast cancer cells. The objectives of the research described in this thesis were to functionally characterize BCAR4, to establish its clinical relevance, and to unravel the mechanisms of tamoxifen resistance induced by BCAR4. The species and tissue specific expression of BCAR4 strongly suggest a role for the gene in mammalian early development and pregnancy. In human breast cancer, high BCAR4 mRNA levels in primary tumors predict tamoxifen resistance, and associate with cancer aggressiveness. BCAR4-induced tamoxifen resistance requires activation of ERBB2 and ERBB3 signaling, but the mechanisms by which BCAR4 activates these receptors are currently unknown. Tamoxifen resistance in breast cancer cells expressing BCAR4 can be reverted by treating them with an ERBB2 inhibitor. This implies that this combination of anticancer agents is more effective at inhibiting proliferation of these cells. BCAR4 expression in primary breast cancer identifies a subgroup of patients that could benefit from ERBB2-targeted therapies combined with tamoxif

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/6892891139<\/a>> # The role of BCAR4 in tamoxifen resistant breast cancer<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:CreativeWork<\/a>, schema:Book<\/a> ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"6892891139<\/span>\" ;\u00A0\u00A0\u00A0\nrdfs:comment<\/a> \"949 $l doctoralthesis<\/span>\" ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/estradiol<\/a>> ; # Estradiol<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/endocrine_therapy<\/a>> ; # Endocrine therapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/tamoxifen_resistance<\/a>> ; # tamoxifen resistance<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/bcar<\/a>> ; # BCAR<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/estrogen_receptor<\/a>> ; # Estrogen receptor<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb3<\/a>> ; # ERBB3<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb2_targeted_therapy<\/a>> ; # ERBB2-targeted therapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/reverse_phase_protein_microarray<\/a>> ; # Reverse-phase protein microarray<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/breast_cancer<\/a>> ; # Breast cancer<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb2<\/a>> ; # ERBB2<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/anchorage_independent_growth<\/a>> ; # Anchorage independent growth<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/4_hydroxytamoxifen<\/a>> ; # 4-hydroxytamoxifen<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/bcar4<\/a>> ; # BCAR4<\/span>\n\u00A0\u00A0\u00A0\nschema:creator<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Person\/godinho_marcia<\/a>> ; # Marcia Godinho<\/span>\n\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2012\/06\/27<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"textabstractBreast cancer is one of the most common cancers in women, and it is the second leading cause of cancer-related deaths, just behind lung cancer. The antiestrogen tamoxifen has been successfully used for over three decades to treat patients with estrogen receptor alpha-positive breast cancer patients. However, resistance to this antiestrogen presents a major problem in the treatment of these patients. The breast cancer antiestrogen resistance 4 (BCAR4) gene was identified earlier as a gene capable of inducing tamoxifen resistance in breast cancer cells. The objectives of the research described in this thesis were to functionally characterize BCAR4, to establish its clinical relevance, and to unravel the mechanisms of tamoxifen resistance induced by BCAR4.The species and tissue specific expression of BCAR4 strongly suggest a role for the gene in mammalian early development and pregnancy. In human breast cancer, high BCAR4 mRNA levels in primary tumors predict tamoxifen resistance, and associate with cancer aggressiveness. BCAR4-induced tamoxifen resistance requires activation of ERBB2 and ERBB3 signaling, but the mechanisms by which BCAR4 activates these receptors are currently unknown. Tamoxifen resistance in breast cancer cells expressing BCAR4 can be reverted by treating them with an ERBB2 inhibitor. This implies that this combination of anticancer agents is more effective at inhibiting proliferation of these cells. BCAR4 expression in primary breast cancer identifies a subgroup of patients that could benefit from ERBB2-targeted therapies combined with tamoxifen treatment. This argues for clinical studies evaluating the value of BCAR4 as a biomarker and the possible benefits of the combined treatments for this patient subgroup.<\/span>\" ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/3984492763<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"The role of BCAR4 in tamoxifen resistant breast cancer<\/span>\" ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"6892891139<\/span>\" ;\u00A0\u00A0\u00A0\nschema:publication<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/#PublicationEvent\/erasmus_university_rotterdam2012_06_27<\/a>> ;\u00A0\u00A0\u00A0\nschema:publisher<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Agent\/erasmus_university_rotterdam<\/a>> ; # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/hdl.handle.net\/1765\/32764<\/a>> ;\u00A0\u00A0\u00A0\nschema:workExample<\/a> <http:\/\/worldcat.org\/isbn\/978-94-6191-312-8<\/a>> ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/6892891139<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Agent\/erasmus_university_rotterdam<\/a>> # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:Agent<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Erasmus University Rotterdam<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Person\/godinho_marcia<\/a>> # Marcia Godinho<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Marcia Godinho<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/4_hydroxytamoxifen<\/a>> # 4-hydroxytamoxifen<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"4-hydroxytamoxifen<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/anchorage_independent_growth<\/a>> # Anchorage independent growth<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Anchorage independent growth<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/bcar<\/a>> # BCAR<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"BCAR<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/bcar4<\/a>> # BCAR4<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"BCAR4<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/breast_cancer<\/a>> # Breast cancer<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Breast cancer<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/endocrine_therapy<\/a>> # Endocrine therapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Endocrine therapy<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb2<\/a>> # ERBB2<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"ERBB2<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb2_targeted_therapy<\/a>> # ERBB2-targeted therapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"ERBB2-targeted therapy<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/erbb3<\/a>> # ERBB3<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"ERBB3<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/estradiol<\/a>> # Estradiol<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Estradiol<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/estrogen_receptor<\/a>> # Estrogen receptor<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Estrogen receptor<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/reverse_phase_protein_microarray<\/a>> # Reverse-phase protein microarray<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Reverse-phase protein microarray<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Thing\/tamoxifen_resistance<\/a>> # tamoxifen resistance<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Thing<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"tamoxifen resistance<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/hdl.handle.net\/1765\/32764<\/a>>\u00A0\u00A0\u00A0\nrdfs:comment<\/a> \"NARCIS<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/worldcat.org\/isbn\/978-94-6191-312-8<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:ProductModel<\/a> ;\u00A0\u00A0\u00A0\nschema:isbn<\/a> \"978-94-6191-312-8<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/#PublicationEvent\/erasmus_university_rotterdam2012_06_27<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:PublicationEvent<\/a> ;\u00A0\u00A0\u00A0\nschema:organizer<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/3984492763#Agent\/erasmus_university_rotterdam<\/a>> ; # Erasmus University Rotterdam<\/span>\n\u00A0\u00A0\u00A0\nschema:startDate<\/a> \"2012-06-27<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n